Pharmacy · Independent exam preparation
Pre-registration Examination Study Guide
Practise safe medicine supply, patient assessment, pharmacy calculations and ethical decisions for SAPC's 2026 pharmacist intern Pre-registration Examination.
By CertMedbry · Updated 30 October 2026
Build the judgement to assess a medicine request, detect a supply error, calculate an accurate preparation and explain a defensible professional decision. This selective guide develops 60 concepts across all six domains of SAPC's 2026 pharmacist intern examination blueprint. The complete scope remains section 3.1 and Tables 7–8 of the official 2026 Intern and Tutor Manual, including entry-level practice across community, institutional, manufacturing and wholesale pharmacy.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and registration pathway does this guide cover?
It covers SAPC's pharmacist intern Pre-registration Examination for entry-level generalist pharmacy practice in South Africa. Academic, community, hospital, manufacturing and wholesale internships contribute to the same examination framework; they are practice sectors rather than separate examinations in this guide. Passing the examination is one component of the broader pre-registration evaluation and does not alone establish eligibility to practise independently.
SAPC — Pharmacist Intern: Pre-Reg Examinations · 2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
Which blueprint applies, and how are its domains weighted?
The currently linked 2026 Intern and Tutor Manual supplies the examination blueprint in Table 7: Public health 15.83%; Safe and rational use of medicines and medical devices 27.50%; Supply of medicines and medical devices 33.00%; Organisation and management skills 5.00%; Professional and personal practice 17.00%; Education, critical analysis and research 1.76%. The printed percentages sum to 100.09%, although the table states 100%; they are preserved here without adjustment. No separate day-level blueprint effective date is established. The 2018 competency standards are a referenced framework, not an alternative examination-year blueprint.
2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns · 2018 Competency Standards for Pharmacists in South Africa — Board Notice 59
How many questions are there, and is a scored or pretest split specified?
Section 3.1 describes a minimum of 120 multiple-choice questions. Table 7 allocates 120 questions across the domains: 19, 33, 40, 6, 20 and 2 respectively. A separate scored-versus-pretest question allocation is not identified in the supplied official evidence. The manual states that each question carries one mark and that there is no negative marking.
2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
How long is the examination, and how are its sections arranged?
The examination has 4½ hours of answering time: two hours for calculations and 2½ hours for general practice. The 2026 manual describes calculations on the first day and general practice on the second, while reserving Council's ability to return to a one-day arrangement. Both sections belong to one examination paper. The manual's prose specifies calculations at not less than 30% and general questions at not more than 70%; the adjacent inequality symbols are inconsistent with that wording.
SAPC — Pharmacist Intern: Pre-Reg Examinations · 2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
What are the delivery method, question styles and adaptivity?
The examination is an open-book assessment on SAPC's online platform. Each scenario-based MCQ has four options and one most appropriate answer. The manual says candidates receive the same questions for that examination in randomised order; it does not describe an adaptive examination. The SAPC webpage describes remote delivery, while the manual allows remote and/or designated-venue arrangements. Use the arrangements communicated for the booked sitting.
SAPC — Pharmacist Intern: Pre-Reg Examinations · 2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
What does the manual say about passing and rewriting?
The results section specifies at least 50% overall, a calculation-section subminimum of 60%, and a general-section subminimum of 50%. Both sections must be passed in the same sitting. An unsuccessful candidate must rewrite both sections even when only one section was unsuccessful. Performance on this guide's short learning test does not estimate whether those requirements will be met.
2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
Which references and preparation requirements matter?
The examination permits specified reference materials, including appropriate textbooks and authorised electronic resources; previous pre-registration examination papers are prohibited during the examination. The compulsory SAPC practice examination familiarises interns with online conditions and does not contribute to their assessment. Entrance requirements also include the applicable internship stage, portfolio achievements and tutor reports. Check the current manual and sitting instructions rather than treating examination booking as automatic eligibility.
SAPC — Pharmacist Intern: Pre-Reg Examinations · 2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
How closely do these concepts, questions and cards follow the blueprint?
The 60 concepts are allocated 9, 16, 20, 3, 10 and 2 across domains 1–6. The 20 questions and 20 flashcards each use 3, 5, 7, 1, 3 and 1. These approximate the larger domain weights while retaining meaningful coverage of every domain. They are selective: the official outline and its calculation categories define the full scope. Table 7's examination-specific competency labels are followed where they differ from the broader competency framework.
2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
These independent learning materials address South African pharmacist intern preparation. The original questions are four-option learning drills, not official SAPC items or a prediction of examination success.
Outline used: 2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns, currently linked by SAPC; section 3.1 and Tables 7–8. The workbook label identifies SAPC's pharmacist intern Pre-registration Examination; the assigned slug is preserved. The manual specifies the 2026 examination year but no separate blueprint effective date was found.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Public health15.83%
1.How does health promotion turn advice into an achievable prevention plan?
Health promotion connects a person's modifiable risks with an action they can realistically sustain. Assess current behaviour, readiness, resources and barriers before offering information. Agree on a specific action and a way to review progress, rather than assuming that knowledge alone changes behaviour. The discriminating clue is whether the plan fits the person's circumstances and produces an observable preventive behaviour, not merely whether comprehensive advice was delivered.
Apply it
A patient wants to become more active but works long shifts. Help them choose a short walking period on selected days, identify a safe route and agree when to review whether the plan was manageable.
Common pitfall: Giving an ambitious standard plan can sound thorough while ignoring feasibility. A patient who cannot implement it has received information without a workable intervention.
2018 Competency Standards for Pharmacists in South Africa — Board Notice 59
2.How should a medicines-information question be framed before searching?
A useful medicines-information response begins by defining the actual decision: the patient or population, medicine, indication, relevant characteristics and required outcome. Establish urgency and distinguish general product information from a patient-specific recommendation. Choose a current, authoritative source appropriate to that question and communicate its limitations. A technically correct statement can still be unsafe when it answers the wrong question or omits a circumstance that changes applicability to the patient.
Apply it
A nurse asks whether a tablet can be crushed. First establish the exact product, formulation, administration route and reason for crushing, then consult formulation-specific information rather than answering from the active ingredient's name alone.
Common pitfall: A familiar brand name does not establish formulation equivalence. Modified-release and other specialised preparations require product-specific assessment before changing how they are administered.
3.When does an access problem require health advocacy?
Health advocacy addresses barriers that prevent people from obtaining appropriate care, rather than treating every missed treatment as an individual failure. Identify whether cost, transport, language, disability, service organisation or medicine availability is driving the problem. Support an appropriate referral or service response, and communicate recurring barriers through suitable professional channels. The key distinction is between helping one patient navigate a barrier and changing a system that repeatedly creates it.
Apply it
Several patients miss medicine collection because transport arrives after the collection window closes. Record the recurring problem and raise a practical scheduling proposal with the service team while helping affected patients arrange continuity of care.
Common pitfall: Repeatedly labelling patients non-adherent can obscure a service barrier. Advocacy should improve access without promising benefits or arrangements that have not been authorised.
2018 Competency Standards for Pharmacists in South Africa — Board Notice 59
4.When is cost-minimisation analysis an appropriate comparison?
Cost-minimisation compares costs only after the relevant alternatives have demonstrated equivalent outcomes. Include costs that differ between alternatives within a stated perspective and time horizon, such as acquisition, administration and monitoring. A lower purchase price alone may not mean a lower total cost. If effectiveness or safety differs materially, a method that explicitly compares outcomes is needed; equivalence is a prerequisite to the analysis rather than its conclusion.
Apply it
Two regimens have established equivalent outcomes. Regimen A costs R200 plus R30 for administration; regimen B costs R170 plus R90. Over the same treatment period, A costs R230 and B R260, favouring A.
Common pitfall: Choosing the lowest acquisition price ignores other relevant costs. Calling treatments equivalent because they share an indication also bypasses the essential evidence requirement.
NSW Health — Engaging an Independent Evaluator for Economic Evaluations
5.How does incremental cost-effectiveness clarify a more expensive treatment?
Incremental cost-effectiveness asks what additional outcome is obtained for the additional cost of one alternative over another. Subtract comparator costs and outcomes before dividing: incremental cost divided by incremental effect. State the outcome unit, perspective and time horizon so the result is interpretable. A treatment that costs more and delivers less is dominated; a treatment that costs more and delivers more requires a judgement about the value of its additional benefit.
Apply it
Programme A costs R100,000 and achieves 80 successful outcomes; B costs R130,000 and achieves 90. The additional R30,000 buys 10 additional successes, giving R3,000 per additional successful outcome under the stated assumptions.
Common pitfall: Dividing each programme's total cost by its outcomes answers an average-cost question. It does not directly identify the cost of switching between alternatives.
2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
6.How should disaster planning protect continuity without losing medicine control?
Disaster preparedness identifies essential services, likely disruptions and the controls needed to continue safe pharmaceutical care. Plan communication, staff responsibilities, alternative storage, stock access and referral arrangements before an emergency. During disruption, prioritise urgent patient needs while preserving product identity, storage requirements and transaction records. The decisive principle is that urgency changes workflow and priorities but does not establish that an unidentified or compromised medicine is suitable for use.
Apply it
Flooding threatens a pharmacy storeroom. Activate the relocation plan, move medicines to an approved protected area, maintain temperature monitoring and document transfers so patients can continue receiving traceable stock during the disruption safely.
Common pitfall: Moving stock quickly into an uncontrolled location can replace one hazard with another. Continuity arrangements must preserve storage conditions, security and product traceability.
2018 Competency Standards for Pharmacists in South Africa — Board Notice 59 · WHO Technical Report Series 1025, Annex 7 — Good Storage and Distribution Practices for Medical Products
7.Which symptom pattern should trigger assessment for tuberculosis?
A cough accompanied by features such as weight loss, night sweats or fever should prompt consideration of tuberculosis and linkage to appropriate assessment. Symptoms identify a need for investigation; they do not establish a diagnosis or justify treating the request as an uncomplicated cough. Assess immediate illness severity, advise measures to reduce respiratory exposure and facilitate evaluation. The discriminating cue is the combination of respiratory and systemic symptoms rather than a demand for cough relief alone.
Apply it
An adult requests cough syrup after several weeks of coughing and reports night sweats and weight loss. Arrange prompt assessment for possible tuberculosis and discuss respiratory hygiene rather than allowing symptomatic treatment to delay investigation.
Common pitfall: Temporary cough relief does not resolve the cause. Conversely, symptoms alone do not establish tuberculosis or authorise initiation of a treatment regimen independently.
8.Why is oral rehydration central to uncomplicated diarrhoea care?
Diarrhoea causes loss of water and electrolytes, making replacement of those losses a central treatment objective. Oral rehydration solution supplies a balanced mixture that supports intestinal absorption of water and salts. Assess hydration and the ability to drink, and identify features requiring medical assessment, including blood in stools, persistent illness or significant dehydration. Hygiene and safe water address transmission, while symptom suppression alone does not correct the principal physiological threat to the patient.
Apply it
An adult with recent watery diarrhoea is alert, drinking and has no blood in the stool. Explain correctly prepared oral rehydration solution, ongoing fluid replacement and hygiene, with clear advice about deterioration or persistent symptoms.
Common pitfall: A medicine that reduces stool frequency may appear effective while dehydration progresses. Plain water alone also does not provide the balanced electrolyte replacement of ORS.
WHO — Diarrhoeal Disease · Adult Primary Care 2026 — Clinical Tool
9.How should a screening result lead to appropriate primary care?
Screening identifies people who may need further assessment; it does not automatically establish a diagnosis. Explain what was measured, whether the method and conditions were suitable, and what confirmation or clinical evaluation is needed. Link the result to symptoms and overall risk rather than interpreting a number in isolation. A useful screening service includes an actionable referral and follow-up pathway, particularly when an abnormal result could otherwise leave the patient anxious but untreated.
Apply it
A community screening result is outside the service's referral range in a patient without acute symptoms. Explain its provisional meaning, document the measurement conditions and arrange the recommended assessment rather than announcing a confirmed diagnosis.
Common pitfall: Repeating a measurement can improve measurement confidence but does not replace the required diagnostic pathway. Acute concerning symptoms need assessment regardless of screening context.
2018 Competency Standards for Pharmacists in South Africa — Board Notice 59
Safe and rational use of medicines and medical devices27.50%
10.How does teach-back reveal whether counselling has worked?
Teach-back asks the patient to explain the plan in their own words so the professional can check the clarity of the explanation. Present a small amount of information, invite an explanation or demonstration, then clarify and check again if needed. Frame the request as a test of your communication rather than the patient's intelligence. Agreement, nodding or saying that instructions are understood provides much weaker evidence that the patient can carry out the plan correctly.
Apply it
After explaining a newly supplied medicine schedule, say that you want to check your explanation and ask the patient to describe how they will take it tomorrow. Correct the misunderstanding they reveal, then repeat the check.
Common pitfall: Asking only whether the patient understands encourages a yes response. Teach-back should be supportive and practical, rather than a memory test that embarrasses them.
11.Why should medical-device counselling include an observed demonstration?
A patient can accurately repeat verbal instructions yet use a device incorrectly. Demonstrate with the relevant device or suitable training aid, then observe the patient performing its steps. Compare performance against that device's instructions, identify the specific error and practise again. Device models can require different preparation, coordination or maintenance. The discriminating evidence is successful performance with the intended device, rather than a general statement that the patient has used similar equipment before.
Apply it
A patient reports little benefit from an inhaler. Before assuming treatment failure, ask them to demonstrate its use with an appropriate training device, identify the missed step and confirm improved technique through another demonstration.
Common pitfall: Instructions remembered from another device may be inappropriate. Correcting technique should accompany assessment of symptoms and adherence, rather than replace review of worsening illness.
Good Pharmacy Practice Manual and Associated SAPC Rules · AHRQ — Tool: Teach-Back
12.How does medicine reconciliation differ from copying a medicine list?
Medicine reconciliation establishes what a patient was actually taking and compares it with intended treatment at a transition of care. Use the patient and appropriate records to verify medicine names, strengths, schedules and recent changes, including non-prescription products. Identify discrepancies and determine whether each is intentional. A copied list may preserve an old error; reconciliation requires resolving differences and communicating an accurate plan to the patient and the next professional responsible for care.
Apply it
A discharge list contains both a previous medicine and its documented replacement. Confirm the intended change with the clinical team, reconcile the record and explain the resulting schedule before the patient resumes treatment at home.
Common pitfall: Two different names may conceal duplicate therapy, while a deliberate change may look like an omission. Resolve intent rather than automatically restoring every previous medicine.
13.How should an interaction's mechanism determine its management?
Oral ciprofloxacin interacts with aluminium- or magnesium-containing antacids. Multivalent cations form complexes with ciprofloxacin in the gastrointestinal tract, reducing its absorption and potentially compromising antibacterial treatment. Administer ciprofloxacin at least two hours before or six hours after the interacting product, as specified in the [ciprofloxacin prescribing information](https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=d23e359d-6d12-38f6-e053-2a95a90a0a88). Establish the exact products and actual administration times before recommending a schedule. This absorption interaction requires separation of administration; routine laboratory monitoring cannot compensate for repeatedly administering the products together.
Apply it
For prescribed ciprofloxacin doses at 08:00 and 20:00, a single aluminium/magnesium antacid dose at 14:00 satisfies both separation requirements: the morning ciprofloxacin precedes the antacid by six hours, and the evening ciprofloxacin follows it by six hours. Check every antacid dose when constructing the schedule. By comparison, starting or stopping another medicine during warfarin therapy can require additional INR testing and dose review; separating administration times does not reliably prevent those interactions.
Common pitfall: An interaction alert does not automatically mean that both medicines must be discontinued. Identify the mechanism and consequence, then select an effective intervention. For ciprofloxacin and multivalent cations, increasing the antibiotic dose or merely watching for treatment failure does not replace the specified administration interval.
Good Pharmacy Practice Manual and Associated SAPC Rules · DailyMed - WARFARIN SODIUM tablet
14.How does renal function inform a dose-adjustment calculation?
Reduced renal elimination can lower medicine clearance and increase exposure at an unchanged maintenance dose. Apply the renal-function method and units required by the medicine's dosing guidance; estimates are not automatically interchangeable. In a simplified exercise where clearance is entirely renal and proportional to creatinine clearance, maintenance dose rate changes in the same ratio. Actual recommendations must also account for the medicine, indication, patient condition and whether dose size or interval should change.
Apply it
A hypothetical protocol states that maintenance dose rate is directly proportional to renal clearance. If clearance falls from 80 to 40 mL/min, a previous 600 mg daily dose rate becomes 300 mg daily under those assumptions.
Common pitfall: A proportional exercise does not establish a universal dosing rule. Non-renal clearance, unstable kidney function and medicine-specific guidance can invalidate that simple relationship.
2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
15.How does dimensional analysis prevent thousand-fold dosing errors?
Dimensional analysis keeps units attached to each quantity so the calculation can be checked independently of its arithmetic. Convert to compatible units before dividing dose by concentration, and confirm that unwanted units cancel. The prefix milli denotes one thousandth and micro one millionth, so one milligram equals one thousand micrograms. A plausible-looking number is insufficient: its unit and order of magnitude must also match the requested quantity and the available formulation.
Apply it
A hypothetical order requires 250 micrograms from a 0.5 mg/mL solution. Convert the concentration to 500 micrograms/mL, then calculate 250 divided by 500, giving 0.5 mL and checking that dose units cancel.
Common pitfall: Dividing 250 by 0.5 without reconciling micrograms and milligrams gives a thousand-fold error. Keep units visible rather than relying on mental conversion alone.
16.Why does powder displacement change reconstitution calculations?
The final volume after reconstitution can exceed the volume of diluent added because the powder contributes to the prepared volume. Calculate concentration using the stated final volume or product's verified final concentration, not automatically the added diluent. Then divide the required mass by that concentration. A reconstitution instruction describes how to obtain the intended preparation; it does not imply that diluent volume and final product volume are interchangeable in subsequent dose calculations.
Apply it
A hypothetical vial contains 500 mg and yields 5 mL after addition of 4.6 mL diluent. Its concentration is 100 mg/mL, so a stated 150 mg dose requires 1.5 mL of reconstituted solution.
Common pitfall: Using 4.6 mL as the final volume overestimates concentration and underestimates the withdrawal volume. Follow product-specific reconstitution instructions rather than estimating powder displacement.
2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
17.How does a sodium chloride equivalent support an isotonicity calculation?
A sodium chloride equivalent expresses the osmotic contribution of a substance as an equivalent mass of sodium chloride. In an exercise using 0.9% sodium chloride as the target, first calculate the target equivalent mass for the final volume. Subtract the equivalents contributed by ingredients already present to find the additional sodium chloride required. This method addresses osmotic contribution; it does not establish chemical compatibility, sterility or the suitability of a preparation for a particular route.
Apply it
For a hypothetical 100 mL preparation, the target is 0.9 g sodium chloride equivalent. If 1 g of an ingredient has an equivalent of 0.2 g, add 0.7 g sodium chloride under the stated formulation assumptions.
Common pitfall: Adding the full target salt amount ignores the solute's existing contribution. An isotonic calculation also cannot establish that the preparation is otherwise safe for administration.
2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
18.How should therapeutic monitoring connect a measured result to a treatment decision?
For warfarin treatment of venous thromboembolism, the target INR is 2.5, with a therapeutic range of 2.0–3.0. INR measures anticoagulant intensity; separately assess bleeding and symptoms suggesting recurrent thrombosis. Warfarin inhibits vitamin K-dependent clotting-factor synthesis and helps prevent clot extension and further thromboembolism; it does not directly dissolve an existing clot. Consequently, improvement in leg pain cannot establish appropriate anticoagulation. The product information specifies daily INR testing during initiation until results stabilise within range, followed by testing generally every one to four weeks according to the clinical situation.
Apply it
A patient receiving stable maintenance warfarin for DVT has an INR of 2.6, no bleeding, no recurrent thrombosis symptoms and no recent medicine or dietary changes. Continue the established prescribed regimen and arrange the next INR in two weeks. Review adherence and changes at follow-up. An INR outside 2.0–3.0 requires assessment of the cause and a treatment decision; an INR above 4.0 increases bleeding risk and warrants prompt clinician review. Major bleeding or suspected recurrent pulmonary embolism requires emergency assessment regardless of the last INR.
Common pitfall: A therapeutic INR does not eliminate bleeding risk, and absence of bruising does not demonstrate adequate anticoagulation. Starting, stopping or irregularly taking another medicine requires additional INR assessment rather than automatically waiting for the routine appointment. Do not apply the VTE target indiscriminately to every mechanical-heart-valve indication.
Good Pharmacy Practice Manual and Associated SAPC Rules · DailyMed - WARFARIN SODIUM tablet
19.How does half-life explain concentration decline in a simple model?
Under first-order elimination, the same fraction of medicine is removed during each equal time interval. After one half-life, half remains; after two, one quarter remains. Use this relationship only when the stated model applies and no additional dose or continuing input changes the calculation. Half-life describes the rate of concentration decline under defined conditions; it does not by itself identify the appropriate dose, therapeutic range or monitoring schedule for a medicine.
Apply it
In a hypothetical model, concentration is 80 units/L and half-life is four hours, with no further input. After eight hours, two half-lives have elapsed, so the predicted concentration is 20 units/L.
Common pitfall: Subtracting a fixed concentration each half-life describes a different process. Also check for ongoing infusion or additional doses before applying the simple halving model.
2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
20.How should a pharmacist assess a request for symptom treatment?
A symptom request requires assessment before a product recommendation. Establish who is affected, symptom nature and duration, severity, associated features, previous treatment, existing illnesses and medicine use. Decide whether the presentation is suitable for pharmacist-initiated care or requires referral, then give clear review and deterioration advice. The requested product is not the clinical problem itself. Safe initial care depends on identifying the decision-changing features and remaining within the practitioner's authorised scope.
Apply it
A customer requests the same remedy used by a relative. Ask about their own symptoms, duration, associated warning features and current medicines before deciding whether self-care advice, a suitable product or referral is appropriate.
Common pitfall: A confident product request can conceal a different condition or contraindication. Prior successful use by another person does not establish suitability for this patient.
21.How should weight-based instructions be translated into a measurable dose?
First determine whether the instruction is expressed per dose or per day. Multiply the stated rate by the appropriate verified weight, then apply any specified maximum and divide a daily total into the prescribed number of doses when required. Convert mass to volume using the available concentration. The calculation must preserve the instruction's time basis: confusing milligrams per kilogram per day with milligrams per kilogram per dose multiplies exposure by the dosing frequency.
Apply it
A hypothetical protocol states 12 mg/kg/day in three equal doses for a 15 kg patient. The daily amount is 180 mg and each dose 60 mg; at 20 mg/mL, each dose measures 3 mL.
Common pitfall: Applying the daily rate at every administration triples the intended daily amount in this example. A correct multiplication cannot compensate for misreading the instruction.
2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
22.How is a body-surface-area dose calculated under a stated protocol?
A body-surface-area instruction expresses dose per square metre rather than per kilogram. Use the protocol's specified method to calculate surface area from the required patient measurements, then multiply by the stated dose rate. Keep units explicit and apply any protocol limits. Surface-area and weight-based instructions are different calculation bases; a result from one cannot be substituted into the other simply because both use patient size to individualise the arithmetic.
Apply it
A hypothetical protocol supplies a calculated surface area of 1.2 m² and an instruction of 50 mg/m² per dose. The required mass is 60 mg; at a supplied concentration of 10 mg/mL, withdraw 6 mL.
Common pitfall: Multiplying a per-square-metre rate by body weight produces incompatible units. Confirm both the prescribed basis and the validity of the supplied patient measurements.
2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
23.Which dyspepsia features make routine symptom treatment inappropriate?
Dyspepsia assessment must distinguish an uncomplicated symptom request from possible serious disease or bleeding. Vomiting blood or passing black, tarry stools requires urgent assessment rather than a trial of routine symptom relief. Clarify the symptom history and relevant medicine exposure, but do not allow a familiar label such as indigestion to override an alarming feature. The referral decision can be justified by the warning sign without establishing the underlying diagnosis in the pharmacy.
Apply it
An adult requests an indigestion remedy and reports vomiting material that looks like blood earlier that day. Facilitate urgent medical assessment rather than supplying a routine course and waiting to see whether symptoms improve.
Common pitfall: Temporary relief after an antacid would not exclude serious disease. A referral trigger identifies risk and urgency, rather than proving a particular diagnosis.
24.What information is required to report a suspected adverse medicine reaction?
Report suspected adverse reactions without waiting for proof of causation. SAHPRA's minimum report elements are a patient identifier, suspect-product details, an event description and reporter contact details. The patient identifier need not be the full name: initials or a patient record number can identify the case while limiting unnecessary disclosure. Anonymous reports are not accepted; protecting the patient's identity from unnecessary exposure does not remove the requirement for an identifiable patient and contactable reporter. Provide chronology, concomitant treatment, relevant medical history and outcome as additional useful information.
Apply it
A patient develops a rash after starting a medicine, although another cause remains possible. Assess the patient's immediate clinical needs and arrange appropriate treatment or referral. Submit a report identifying the patient by initials or record number, describing the suspect medicine and rash, and providing the reporter's contact details. Add treatment start and rash onset dates, other medicines and any subsequent improvement or deterioration. These details support assessment without claiming that the medicine definitely caused the rash.
Common pitfall: A detailed chronology cannot replace a missing patient identifier or reporter contact details. Equally, uncertainty about causality is not a reason to withhold a report that contains the minimum elements. Reporting and urgent clinical care are separate responsibilities; completing a form must not delay necessary treatment.
25.How do consent and product accountability protect clinical-trial participants?
Clinical-trial participation requires appropriate informed consent and conduct according to the approved protocol. Pharmacy responsibilities include maintaining investigational-product identity, storage, authorised supply and accountability records. Randomisation assigns treatment according to the study method; it is not permission to substitute products or disclose a blinded allocation informally. The important distinction is between ordinary stock availability and protocol-authorised supply to an eligible participant with the required safeguards and documentation in place.
Apply it
A trial participant arrives for a refill, but the allocation record and requested pack do not agree. Stop the supply, preserve blinding and resolve the discrepancy through the authorised study process before dispensing the investigational product.
Common pitfall: A commercially similar product is not automatically an acceptable trial substitute. Consent also does not remove the participant's right to ask questions or withdraw.
2018 Competency Standards for Pharmacists in South Africa — Board Notice 59 · Good Pharmacy Practice Manual and Associated SAPC Rules
Supply of medicines and medical devices33.00%
26.Why must packaging line clearance precede a new operation?
Line clearance verifies that the packaging area, equipment and relevant materials are free from remnants of previous operations and unsuitable items before the next operation begins. Previous labels, product or documents can create mix-ups even when the new batch's formulation is correct. Use the approved procedure and record the check. The discriminating cue is a verified clean starting state; a general cleaning record alone does not demonstrate that obsolete packaging materials have been removed.
Apply it
Before a new product is packaged, an operator finds labels from the previous batch near the line. Suspend startup, remove and account for them, and complete the required clearance verification before authorising the operation.
Common pitfall: Assuming that an idle or visibly tidy line is cleared overlooks concealed labels and documents. Cleaning and line clearance address overlapping but different hazards.
PIC/S Guide to Good Manufacturing Practice for Medicinal Products, PE 009-18, Part I · SAHPRA — Guidelines to Good Manufacturing Practice for Medicines, version 9
27.Why is a passing laboratory result insufficient for batch release?
Batch release requires assurance that manufacture and control complied with the approved requirements, not merely that a sample passed testing. Review production and packaging records, deviations, reconciliation, required results and relevant quality decisions before release by authorised personnel. Testing examines selected attributes of samples; it cannot independently prove that every processing and documentation requirement was met. A significant unresolved deviation therefore remains a release concern even when the available laboratory results are within specification.
Apply it
A batch meets finished-product specifications, but a documented processing deviation has not been assessed. Keep the batch under controlled status while the investigation and authorised release review determine whether the deviation compromises its acceptability.
Common pitfall: A certificate of analysis does not erase an unresolved manufacturing problem. Release responsibility cannot be replaced by a production deadline or an informal assurance.
SAHPRA — Guidelines to Good Manufacturing Practice for Medicines, version 9
28.How does packaging reconciliation reveal an unexplained discrepancy?
Reconciliation compares materials issued with quantities used, returned, rejected or destroyed using categories defined by the approved process. Every quantity should be traceable, and an unexplained difference requires investigation rather than automatic assignment to wastage. This is especially important for printed packaging materials because an unexplained label may represent a product mix-up. A calculation identifies the discrepancy; its significance and disposition require the relevant quality process and documented assessment before release.
Apply it
A line receives 10,000 labels, uses 9,600, returns 250 and documents destruction of 100. The remaining 50 labels are unexplained, so the discrepancy must be investigated rather than silently added to the destruction total.
Common pitfall: A small percentage discrepancy can still matter for printed materials. Reclassifying missing labels as waste without evidence makes the arithmetic balance while concealing risk.
SAHPRA — Guidelines to Good Manufacturing Practice for Medicines, version 9
29.How should manufacturing yield be calculated and interpreted?
Percentage yield compares actual acceptable output with the relevant theoretical or expected output on a consistent basis. Divide actual output by theoretical output and multiply by one hundred. Confirm which stage, units and exclusions the approved definition uses before calculating. An unusual result can indicate loss, measurement error, recording error or an incorrect input assumption. Yield is a process-control signal; a numerically acceptable yield does not independently establish product quality or authorise release.
Apply it
A hypothetical granulation step has a theoretical output of 50 kg and an acceptable recovered output of 47.5 kg. Yield is 95%; compare that result with the approved limits and investigate any required discrepancy.
Common pitfall: Using total material including rejected output can overstate acceptable yield. Different manufacturing stages may also use different denominators, so apparently similar percentages may not be comparable.
2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns · SAHPRA — Guidelines to Good Manufacturing Practice for Medicines, version 9
30.How is a master formula scaled without changing composition?
Calculate a scale factor by dividing the required batch size by the master formula's batch size, then apply it consistently to each scalable ingredient. Preserve the intended concentration and account correctly for any vehicle specified to a final quantity. Arithmetic scaling does not demonstrate that equipment, mixing or processing conditions remain suitable at the new scale. A scaled formula therefore needs both an accurate composition calculation and the applicable manufacturing or compounding controls.
Apply it
A hypothetical master formula makes 200 g using 4 g of ingredient A and vehicle to final mass. To prepare 750 g, use a factor of 3.75, giving 15 g A and vehicle to 750 g.
Common pitfall: Adding the full final mass as vehicle overshoots the intended batch size. Correct ingredient proportions also do not automatically validate processing at a larger scale.
2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
31.Which receiving checks distinguish acceptable stock from stock needing quarantine?
Receiving controls verify that delivered products match authorised orders and arrive in an acceptable condition. Check identity, quantity, packaging integrity, batch and expiry information, supplier documentation and required transport conditions. Separate products with unresolved discrepancies or suspected damage from usable stock until assessed. An invoice proves a commercial transaction, not product suitability. Quarantine preserves a controlled status so a questionable product cannot enter routine distribution while its identity, quality or transport history remains unresolved.
Apply it
A delivery matches the order quantity, but several packs are water-damaged and their batch details are unreadable. Segregate the affected packs, document the discrepancy and seek an authorised disposition rather than shelving the entire delivery.
Common pitfall: Signing a delivery note does not establish quality acceptance. Mixing questionable packs with usable stock makes later identification and control more difficult for staff.
32.How should a cold-chain excursion be managed?
A temperature excursion requires identification and controlled segregation of affected stock, preservation of temperature records and an assessment using product-specific stability information. Record the temperature range, duration and relevant circumstances, then obtain an authorised decision before use or disposal. Returning stock to the recommended temperature does not reverse possible deterioration. Equally, an excursion alone does not establish that every affected product must be destroyed; the disposition depends on an evidence-based quality assessment.
Apply it
A refrigerator logger records an overnight excursion. Mark affected stock as unavailable for routine supply, maintain appropriate storage, save the logger data and obtain a documented product-specific assessment before any of those packs are released.
Common pitfall: A normal current temperature can hide an earlier excursion. Neither automatic release after cooling nor automatic destruction substitutes for a documented assessment of affected products.
Good Pharmacy Practice Manual and Associated SAPC Rules · WHO Technical Report Series 1025, Annex 7 — Good Storage and Distribution Practices for Medical Products
33.Why does first-expiry-first-out usually outrank arrival order?
First-expiry-first-out prioritises acceptable stock with the earliest expiry date, reducing avoidable expiry while maintaining sufficient remaining shelf life for the intended use. Arrival order is an unreliable substitute because a later delivery may expire sooner. Stock rotation applies only after confirming quality status and suitability. A quarantined or recalled pack does not become eligible for supply merely because its expiry date makes it the first pack that would otherwise be selected.
Apply it
Two acceptable batches arrive in different months, but the newer delivery expires first. Place that batch earlier in the picking sequence, provided its remaining shelf life is adequate for the intended patient or receiving service.
Common pitfall: Selecting the oldest delivery can leave earlier-expiring stock unused. FEFO also does not override a hold, recall, damage finding or inadequate remaining shelf life.
34.How is a reorder point calculated from demand and lead time?
A basic reorder point covers expected consumption during supplier lead time plus a defined safety stock. Keep demand and lead-time units consistent, then consider whether the exercise uses stock on hand or an inventory position that includes outstanding orders and commitments. Safety stock buffers uncertainty; it is not a second estimate of routine lead-time use. Real systems must also address changing demand, variable lead times and stock that is unavailable because of its quality status.
Apply it
A hypothetical item is used at 40 units daily, takes six days to arrive and requires 80 units of safety stock. The basic reorder point is 40 × 6 + 80, or 320 usable units.
Common pitfall: Ordering only when safety stock is reached ignores lead-time demand. Counting quarantined stock as available also makes the apparent stock position misleading for replenishment.
2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
35.How does ABC analysis guide inventory attention?
ABC analysis ranks items by consumption value, commonly calculated as quantity used over a defined period multiplied by unit cost. Items accounting for the largest share of expenditure receive closer financial control. The method identifies where money is concentrated, not which medicines are most clinically essential. Combine expenditure analysis with clinical criticality and supply risk so a low-cost but indispensable item is not neglected simply because it contributes little to the total inventory budget.
Apply it
Item A costs R1 and uses 100,000 units annually; item B costs R50 and uses 500. Their annual values are R100,000 and R25,000, so A warrants greater expenditure attention despite its lower unit price.
Common pitfall: Ranking only by unit price misidentifies expenditure priorities. ABC category alone also cannot decide which item deserves emergency replenishment when clinical consequences differ.
2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
36.How should a formulary decision combine evidence and service needs?
Formulary development compares medicines using clinical need, effectiveness, safety, quality, practical suitability and relevant costs. Consider whether the service can store, administer and monitor the proposed option appropriately. A transparent process should document the evidence and decision criteria, including how exceptions are handled. The cheapest product is not necessarily the best formulary choice, and a promotional claim does not establish comparative benefit. Selection should support consistent, rational treatment within the healthcare setting.
Apply it
A proposed medicine has a lower purchase price but requires monitoring unavailable at the facility. Present its total service requirements and alternatives to the formulary committee instead of recommending inclusion on acquisition cost alone.
Common pitfall: Popularity or supplier incentives can distort selection. A formulary also needs an appropriate review and exception process rather than treating every patient circumstance as identical.
2018 Competency Standards for Pharmacists in South Africa — Board Notice 59
37.How should prescription assessment separate validity from clinical suitability?
A prescription must meet the applicable legal requirements and be clinically appropriate for the patient. Verify the prescriber, patient and required particulars, then assess the medicine, dose, route, schedule and relevant patient risks. A legally complete prescription can still contain a clinical error, while an apparently reasonable treatment may require clarification of an incomplete instruction. Resolve decision-changing ambiguities before supply rather than inferring missing information from habit or assuming that authorisation guarantees safety.
Apply it
A prescription identifies the medicine and patient but contains conflicting dose instructions. Compare the available clinical information and contact the prescriber to establish one clear authorised instruction before preparing the final label and supply.
Common pitfall: Guessing the intended dose transfers an unresolved ambiguity to the patient. A prescriber's signature does not remove the pharmacist's responsibility to assess the order.
38.How does a final dispensing check prevent selection errors?
The final check compares the authorised instruction with the selected product, prepared quantity, label and intended patient before supply. Verify strength, dosage form and other relevant product characteristics rather than relying on pack colour or shelf position. The check should detect a mismatch introduced anywhere in preparation. Familiarity creates a particular risk when products look alike: a label can be internally consistent yet still describe a different medicine from the one inside the pack.
Apply it
Two strengths have similar packaging and are stored together. During the final check, compare the physical pack's strength with the prescription and label, correct the mismatch and review how the storage arrangement contributed to selection.
Common pitfall: Checking only the label can miss a correctly printed label attached to the wrong product. Visual familiarity is weaker evidence than direct identity verification.
39.How should a liquid-medicine supply make the intended dose usable?
A usable liquid-medicine supply connects the prescribed mass dose with the product concentration and a clearly stated measurable volume. Confirm that the measuring device can accurately deliver that volume and explain relevant preparation or storage instructions. Where appropriate, observe the patient or caregiver measuring a dose. A numerically correct label is not enough if the volume cannot be measured reliably, the wrong concentration was selected or the instructions invite use of an unsuitable household utensil.
Apply it
A hypothetical prescription requires 2.5 mL per dose. Supply an appropriate graduated device, show the correct marking and ask the caregiver to demonstrate measuring 2.5 mL rather than relying on their estimate of a spoonful.
Common pitfall: Household spoons are not reliable measuring devices. A familiar millilitre instruction also becomes unsafe if a different concentration is supplied without reconciling the dose.
Good Pharmacy Practice Manual and Associated SAPC Rules · AHRQ — Tool: Teach-Back
40.How is the quantity for a complete treatment course calculated?
Calculate the amount per administration, the number of administrations and the duration using compatible units. For a liquid, convert each mass dose to volume before multiplying, or calculate total mass and divide by concentration as an independent check. Distinguish a stated course length from an assumed pack size. The required supply must match the authorised regimen, while any packaging or stability constraint should be addressed explicitly rather than changing the instructions to fit stock.
Apply it
A hypothetical order specifies 5 mL three times daily for seven days. The required quantity is 5 × 3 × 7 = 105 mL; verify that the supplied preparation remains suitable throughout the intended course.
Common pitfall: Using a convenient bottle size as the calculation's starting point can under-supply treatment. Also distinguish administrations per day from intervals stated in hours.
2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
41.How is an infusion dose rate converted into a pump rate?
Convert the prescribed dose rate into mass per unit time, then divide by the final infusion concentration to obtain volume per unit time. Weight-based instructions require multiplication by the stated patient weight, and minute-to-hour conversion must be explicit when relevant. Use the concentration of the final infusion, not automatically the original vial. The resulting pump rate should be checked against the preparation record and order before administration under the applicable clinical process.
Apply it
A hypothetical order is 0.4 mg/kg/hour for an 18 kg patient, using a final solution containing 60 mg in 100 mL. Required delivery is 7.2 mg/hour; dividing by 0.6 mg/mL gives 12 mL/hour.
Common pitfall: Confusing vial concentration with final infusion concentration can produce a major rate error. A correct pump rate also depends on preparing the stated solution correctly.
2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
42.How should percentage strength be translated into a dilution?
Interpret the percentage basis before calculating: mass per volume, mass per mass and volume per volume are different statements. For compatible volume-based concentrations, conservation of solute gives C1V1 = C2V2. Calculate the required stock quantity and add suitable vehicle to the specified final volume. The final-volume instruction matters because adding a volume equal to the target batch size to the stock would create a larger and more dilute preparation.
Apply it
Prepare a hypothetical 250 mL of 4% solution from compatible 20% stock. Required stock is 4 × 250 ÷ 20 = 50 mL; add suitable vehicle to a final volume of 250 mL.
Common pitfall: Adding 250 mL vehicle to 50 mL stock exceeds the target volume. The dilution equation also requires compatible concentration definitions and a suitable vehicle.
2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
43.How does alligation determine proportions of two compatible strengths?
When combining compatible preparations on the same concentration basis, the target strength must lie between the two starting strengths. Conservation of active ingredient determines the required proportions. The amount of stronger preparation is proportional to the difference between target and weaker strengths; the weaker amount is proportional to the difference between stronger and target strengths. This arithmetic determines composition only and cannot establish that mixing the preparations is pharmaceutically appropriate or stable.
Apply it
For a hypothetical 100 g mixture of 10% and 2% compatible preparations to make 4%, the strong-to-weak ratio is 2:6, or 1:3. Use 25 g of 10% and 75 g of 2%.
Common pitfall: Equal quantities give the midpoint strength, not any desired target. A mathematically valid ratio does not establish compatibility between different bases or formulations.
2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
44.Why must a compounded preparation have a defensible record and use period?
Compounding requires an appropriate formula, suitable ingredients and equipment, accurate preparation and a record that makes the product traceable. Document quantities, calculations, ingredient details, preparation checks and relevant labelling or storage instructions. The assigned use period must be supported by the formulation and applicable evidence or standards. A raw ingredient's expiry date does not establish the compounded preparation's stability because mixing, packaging and storage can change the conditions that determine product quality.
Apply it
A pharmacist prepares an extemporaneous liquid from an approved formula. Record ingredient batches, actual quantities, final volume, checks, storage and supported use period so another professional can investigate or reproduce the preparation if needed later.
Common pitfall: Copying the longest ingredient expiry onto the final product ignores formulation stability. An undocumented preparation also cannot be reliably investigated when a quality concern emerges.
45.How should unwanted medicines remain controlled through disposal?
Expired, recalled, damaged and otherwise unsuitable medicines must be separated from usable stock and managed through an authorised disposal or return process. Preserve identity and relevant records, restrict access and follow requirements appropriate to the product and waste category. Removal from the dispensing shelf is only the first control. The process must prevent accidental resupply, diversion and inappropriate environmental release while providing evidence of the final authorised disposition of the affected stock.
Apply it
A stock review identifies expired packs and a separate recalled batch. Segregate and clearly identify both groups, maintain their records and follow the applicable authorised return or destruction arrangements rather than mixing them with ordinary refuse.
Common pitfall: A container labelled waste can still be accessible for diversion or accidental reuse. Disposal arrangements must reflect product hazards and legal requirements, not convenience.
Good Pharmacy Practice Manual and Associated SAPC Rules · WHO Technical Report Series 1025, Annex 7 — Good Storage and Distribution Practices for Medical Products
Organisation and management skills5.00%
46.How should staffing and delegation match competence and workload?
Safe staffing requires defined responsibilities, appropriate competence and supervision matched to the work being performed. Assess training needs and workload rather than assuming that a job title or length of service establishes competence for every task. Delegation assigns a task within permitted boundaries; it does not remove the need for oversight and escalation arrangements. A management response should address both the immediate workload risk and the system that repeatedly places staff beyond their capability.
Apply it
A newly appointed staff member is asked to perform an unfamiliar preparation during a busy period. Reassign or supervise the task, verify competence before future independent work and review staffing arrangements that created the unsafe pressure.
Common pitfall: Speed and confidence can conceal a training gap. Delegating an activity beyond a worker's permitted role cannot be corrected merely by giving clearer instructions.
2018 Competency Standards for Pharmacists in South Africa — Board Notice 59 · SAPC — Responsible Pharmacist: Responsibilities
47.How should a pharmacy budget account for infrastructure risk?
Financial management should connect expenditure with the service's safety and operational requirements. Distinguish purchase price from ongoing costs such as maintenance, monitoring, calibration, training and contingency arrangements. Infrastructure that cannot reliably maintain required conditions can create losses and interrupt care even when it was inexpensive to acquire. A defensible budget prioritises essential controls, compares realistic total costs and makes the consequences of deferred maintenance visible to those responsible for resource decisions.
Apply it
Two refrigerator proposals differ in price and service support. Compare monitoring, maintenance, backup arrangements and likely interruption costs, then document why the recommended option best supports required storage conditions within the pharmacy's available budget.
Common pitfall: Treating maintenance as an optional saving can transfer costs into stock loss and service interruption. A budget variance alone does not identify its cause.
2018 Competency Standards for Pharmacists in South Africa — Board Notice 59 · SAPC — Responsible Pharmacist: Responsibilities
48.How do corrective action and change control turn an incident into improvement?
Quality improvement distinguishes immediate correction from action on the cause of a problem. Contain the risk, investigate contributing factors, implement proportionate corrective or preventive action and check whether recurrence decreases. When a change affects practice, assess its risks, update controlled procedures, train affected staff and monitor implementation. A policy document alone does not establish improvement. The decisive evidence is that the revised process is used and addresses the mechanism that produced the original failure.
Apply it
Repeated picking errors involve two adjacent look-alike packs. Correct affected supplies, investigate the selection process, redesign storage and update the procedure, then audit later picks to determine whether the change reduced that specific error pattern.
Common pitfall: Retraining everyone may be tempting but ineffective when storage design drives the error. Closing an action without checking effectiveness confuses completion with improvement.
SAPC — Responsible Pharmacist: Responsibilities · Good Pharmacy Practice Manual and Associated SAPC Rules
Professional and personal practice17.00%
49.How should patient-centred care address an impractical plan while protecting confidentiality?
Explore the patient's goals, work demands and privacy concerns, then discuss safe, feasible treatment options. If involving an employer or relative would help, ordinary consent-based disclosure requires the patient's written consent. Verify the recipient's identity and the authorised information and purpose before disclosure. National Health Act section 14 also permits disclosure when a court order or law requires it, or when nondisclosure represents a serious threat to public health. Section 15 separately permits necessary disclosure for a legitimate purpose within the ordinary course and scope of duties, in the patient's interests. SAPC Code section 1.3 reinforces the duty of confidentiality.
Apply it
A patient struggles with a treatment schedule at work and fears that the employer will learn the medicine's name. Explore suitable schedule changes with the care team. If the patient wants workplace support, obtain written consent specifying the recipient and limited information authorised for release, then verify that recipient. A request for schedule accommodation does not itself authorise disclosure of the entire medicine history. Necessary information sharing with a treating healthcare provider must satisfy section 15's conditions.
Common pitfall: A relative's concern, an employer's request or the caller's knowledge of a medicine name does not itself authorise confirmation. Distinguish ordinary third-party disclosure requiring written consent from the specific care-related and statutory exceptions. Patient-centred care supports informed choices while preserving professional, safety and confidentiality obligations.
2018 Competency Standards for Pharmacists in South Africa — Board Notice 59 · SAPC — Rules Relating to the Code of Conduct · NHREC-Training-National-Health-Act-see-Chapter-9-definition-of-Health-research.pdf
50.When may confidential medicine information be shared?
Medicine information is confidential even when a requester is a relative, employer or familiar member of the community. Establish the patient's consent or another valid legal basis, verify the requester's identity and disclose only information appropriate to the purpose. Necessary communication within care should also respect confidentiality safeguards. The decisive issue is authority to receive the information, not whether the requester sounds concerned or already knows part of the patient's health history.
Apply it
An employer calls to confirm a worker's medicine and diagnosis. Explain that you cannot disclose confidential details without an appropriate basis, and offer to discuss a properly authorised request through the pharmacy's established process instead.
Common pitfall: Confirming that a named person receives a particular medicine can itself disclose sensitive information. Familiarity and good intentions do not establish permission to share.
51.How should informed consent support a patient's treatment decision?
Informed consent requires understandable information about the proposed care, relevant benefits and risks, reasonable alternatives and an opportunity to decide voluntarily. Check understanding and address communication barriers rather than treating a signature as the entire process. A patient who can make the relevant decision may decline a recommendation after discussion. Capacity and consent are decision-specific concerns; disagreement with professional advice alone does not demonstrate that the patient is unable to make an informed choice.
Apply it
A patient declines a recommended service after discussing its purpose and alternatives. Explore unresolved questions, confirm understanding, document the decision and explain appropriate follow-up while respecting a voluntary choice made with adequate information and understanding.
Common pitfall: Pressuring a patient until they agree undermines voluntariness. Equally, handing over a form without checking comprehension does not establish an adequate consent discussion.
SAPC — Rules Relating to the Code of Conduct · 2018 Competency Standards for Pharmacists in South Africa — Board Notice 59
52.Why can a referral commission compromise professional independence?
Professional recommendations should be based on patient needs and appropriate care rather than a payment linked to steering business. A personal commission for directing patients to a particular provider creates a conflict that can distort judgement and undermine trust. Disclosure alone does not make an improper inducement acceptable. Distinguish legitimate payment for an authorised professional service from a reward whose purpose is to influence where patients obtain treatment or products for commercial gain.
Apply it
A business offers a pharmacist a personal payment for every patient referred to its service. Decline the arrangement and continue recommending services according to suitability, accessibility and patient preference rather than the promised commission.
Common pitfall: The absence of an extra patient charge does not remove the conflict. A benefit can improperly influence professional judgement even when the patient pays the usual price.
53.How does direct personal supervision define pharmacist intern practice?
The 2026 manual describes pharmacist intern acts as education and training performed under the direct personal supervision of a pharmacist in a pharmacy. Exposure to the pharmacist's scope develops competence but does not create independent authority to perform those acts without the required supervision. The relevant decision is whether the planned activity, setting and supervision meet the applicable requirements. Previous successful performance does not remove the supervision requirement during internship or expand the intern's registration category.
Apply it
An intern is asked to cover a pharmacy activity while no supervising pharmacist is available. Identify the supervision problem and arrange compliant cover rather than treating prior experience with the task as permission to proceed independently.
Common pitfall: Confidence and near-completion of internship do not change registration status. A pharmacist being contactable by telephone should not be assumed to satisfy direct personal supervision.
2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
54.How does accurate documentation support professional accountability?
Professional records should make the relevant facts, assessment, action, communication and follow-up understandable to another authorised professional. Record what occurred accurately and promptly, distinguishing observations from assumptions. Corrections should preserve the record's integrity rather than conceal the original information. Documentation supports continuity and investigation, but it cannot make an unsafe action acceptable. The test is whether the record explains the decision and responsibilities clearly enough to support appropriate subsequent care or quality review.
Apply it
A pharmacist clarifies an ambiguous instruction with the prescriber. Record the clarification, who authorised it, the resulting instruction and the communication to the patient so the next professional can understand and follow the resolved plan.
Common pitfall: Writing only 'doctor contacted' leaves the decision unresolved for others. Retrospective reconstruction should not be presented as a contemporaneous record of facts that were never verified.
Good Pharmacy Practice Manual and Associated SAPC Rules · SAPC — Rules Relating to the Code of Conduct
55.How should a pharmacist maintain care when a request exceeds professional competence?
Recognising a competence boundary is part of professional practice. Identify the unresolved risk, explain the limitation clearly and arrange suitable assistance or referral while addressing immediate needs within your authority. Do not imply expertise that you do not possess, and do not allow a referral to become an unexplained dismissal. The appropriate response combines an honest boundary with a practical care pathway so the patient understands what happens next and why it matters.
Apply it
A patient asks for a specialised assessment outside the pharmacist's competence. Explain the concern, identify an appropriate service and provide relevant information for continuity, while escalating any urgent features instead of simply declining to help.
Common pitfall: Attempting an unfamiliar intervention to appear helpful can increase risk. Referring without explaining urgency or access arrangements can also leave the patient without effective care.
SAPC — Rules Relating to the Code of Conduct · 2018 Competency Standards for Pharmacists in South Africa — Board Notice 59
56.How does leadership show itself when a colleague identifies a safety concern?
Professional leadership includes creating conditions in which staff can raise concerns and receive a reasoned response. Listen to the specific evidence, protect the patient or product where necessary, and use the appropriate escalation pathway. Seniority does not determine whether a concern is valid. Effective leadership separates immediate risk control from later review of individual and system contributions, while ensuring that the person who raised the issue receives feedback about the resulting action.
Apply it
An assistant notices that a prepared pack's strength differs from its label just before collection. Pause supply, verify the discrepancy and thank them for raising it, then investigate how the mismatch arose and share the learning.
Common pitfall: Dismissing a concern because a senior person checked the work discourages future reporting. A respectful response still requires verification rather than accepting every allegation uncritically.
2018 Competency Standards for Pharmacists in South Africa — Board Notice 59 · 2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
57.How should uncertainty be handled in a professional decision?
A defensible decision identifies the problem, decision-changing facts, realistic options and consequences before choosing an action within professional authority. Separate missing information from established facts and consider the harm of delay as well as the harm of acting. Seek targeted clarification when it could change the choice, and document the reasoning for significant decisions. Uncertainty does not justify guessing, but neither does it automatically justify postponing a time-sensitive action that is clearly needed.
Apply it
A prescription has an unclear dose and the patient has enough existing supply until tomorrow. Arrange targeted clarification before dispensing, documenting the plan, rather than guessing or describing the situation as an emergency without supporting evidence.
Common pitfall: Gathering every conceivable fact can delay an already clear urgent action. Conversely, acting quickly is not defensible when a critical ambiguity remains safely resolvable.
2018 Competency Standards for Pharmacists in South Africa — Board Notice 59
58.How does reflection turn a competence gap into improved professional practice?
Reflection connects an observed performance gap with a specific learning activity and a check of subsequent improvement. Identify what you could not explain or perform, determine why it matters, obtain suitable learning or supervised practice and reassess the skill. Attendance at training is evidence of participation, not necessarily competence. A meaningful professional-development cycle demonstrates a change in knowledge, behaviour or performance that addresses a real practice need rather than merely accumulating completed activities.
Apply it
An intern repeatedly confuses daily and per-dose instructions. Use supervised calculation cases focused on that distinction, explain the reasoning aloud and review later independent work to determine whether the identified error pattern has actually improved.
Common pitfall: Choosing convenient training unrelated to the observed gap may add activity without improving practice. Self-confidence alone is also an unreliable measure of demonstrated competence.
2018 Competency Standards for Pharmacists in South Africa — Board Notice 59 · 2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
Education, critical analysis and research1.76%
59.How can confounding make an observational treatment comparison misleading?
Confounding occurs when differences associated with treatment choice also influence the outcome, creating or distorting an observed association. A treatment group may appear healthier because its patients began with different risks or healthcare access. Statistical adjustment addresses measured factors only to the extent the data and model permit. Negative controls can help detect residual bias when they show associations that should not arise from the proposed treatment effect, but they do not automatically identify or remove every source of bias.
Apply it
An observational study finds better outcomes among users of a new medicine, but those users also have fewer baseline illnesses. Examine how the study addressed those differences before interpreting the association as evidence of treatment benefit.
Common pitfall: A large sample narrows random uncertainty without necessarily removing systematic bias. An adjusted estimate should not be treated as proof that all confounding has disappeared.
FDA — Evaluating Negative Controls in Drug Safety and Effectiveness Studies
60.How should a research question determine the study's outcome and design?
A focused research question specifies the population, intervention or exposure, comparator and outcome needed to answer it. Choose a design and measurement plan capable of distinguishing the proposed explanation from plausible alternatives. Define important outcomes and analysis methods in advance, and obtain appropriate ethical oversight for research involving people or their information. A convenient measure is not automatically a valid measure of the question, and a statistically detectable change may lack practical or clinical importance.
Apply it
A team wants to know whether counselling improves correct device use. Define a standard observed-technique outcome and comparison approach before collecting data, rather than measuring satisfaction alone and later treating it as evidence of improved technique.
Common pitfall: Changing the main outcome after seeing results can produce a misleading success claim. Ethical approval and data protection are also separate from statistical quality.
2018 Competency Standards for Pharmacists in South Africa — Board Notice 59
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Give the largest share of study time to medicine supply: dispensing, compounding, GxP, supply-chain controls and their calculations.
- Practise pharmacist-initiated care as an assessment decision, including referral cues, scope boundaries and clear follow-up advice.
- Calculate with visible units and stated assumptions, especially daily versus per-dose instructions, displacement volume, final concentration and infusion time units.
- Connect every quality incident to controlled stock status, traceable evidence, authorised disposition and an effectiveness check where appropriate.
- Distinguish confidentiality, consent, professional independence and supervision requirements from commercial pressure or personal confidence.
- Use familiar authorised references to confirm decision-changing details efficiently, while studying the complete official outline beyond this selective guide.
A practical preparation plan
1. Map the complete 2026 scope
Work through Table 7 and the calculation categories in Table 8. Mark each competency as demonstrated, needing practice or unfamiliar, including sectors outside your current placement.
2. Build a calculation method
Write the requested quantity and units first, identify the relevant final concentration or time basis, calculate and check plausibility. Rework errors by their cause rather than memorising an answer.
3. Practise decisions across sectors
Alternate patient-care cases with dispensing, manufacturing, wholesale and management problems. Explain the decisive cue, the unsafe alternative and the professional action required.
4. Organise usable references
Become familiar with the location of legal requirements, product information, clinical guidance and GPP/GMP controls in the materials authorised for your sitting.
5. Review reasoning after each drill
Answer the 20 questions before reading their explanations. For every error, identify whether the cause was missing knowledge, a missed cue, an incorrect assumption or arithmetic.
6. Rehearse the official conditions
Complete SAPC's compulsory practice examination, follow the current technical instructions and rehearse section timing. Review calculation and general-practice weaknesses separately because both sections have subminimum requirements.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- SAPC — Pharmacist Intern: Pre-Reg Examinations
- SAPC — Intern Manual
- 2026 Intern and Tutor Manual for the Pre-registration Experience of Pharmacist Interns
- 2018 Competency Standards for Pharmacists in South Africa — Board Notice 59
- Good Pharmacy Practice Manual and Associated SAPC Rules
- SAPC — Rules Relating to the Code of Conduct
- SAHPRA — Health Products Vigilance
- AHRQ — Tool: Teach-Back
- WHO Technical Report Series 1025, Annex 7 — Good Storage and Distribution Practices for Medical Products
- SAHPRA — Guidelines to Good Manufacturing Practice for Medicines, version 9
- NIST Guide to the SI — Chapter 4
- FDA — Evaluating Negative Controls in Drug Safety and Effectiveness Studies
- SAPC — Responsible Pharmacist: Responsibilities
- NSW Health — Engaging an Independent Evaluator for Economic Evaluations
- PIC/S Guide to Good Manufacturing Practice for Medicinal Products, PE 009-18, Part I
- Adult Primary Care 2026 — Clinical Tool
- WHO — Diarrhoeal Disease
- Tuberculosis
- Determining Drug Dosing in Adults with Chronic Kidney Disease - NIDDK
- NHREC-Training-National-Health-Act-see-Chapter-9-definition-of-Health-research.pdf
- SA-GCP-2020_Final.pdf
- Guidelines
- DailyMed - WARFARIN SODIUM tablet
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.